Published in PLoS One on June 27, 2016
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine (Baltimore) (2017) 0.75
The immunology of mucosal models of inflammation. Annu Rev Immunol (2001) 9.08
Ulcerative colitis. N Engl J Med (2011) 6.14
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology (2015) 3.84
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol (2012) 3.38
Cytokines in inflammatory bowel disease. Nat Rev Immunol (2014) 3.24
Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology (1993) 3.20
Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology (2015) 3.12
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74
Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr (2013) 2.57
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood (2011) 2.47
Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther (2014) 2.37
Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust (1989) 2.16
Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology (2009) 2.15
IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med (2012) 2.11
Function of C-reactive protein. Ann Med (2000) 2.10
Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe (2012) 1.81
Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis (2013) 1.79
Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet (1989) 1.76
Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med (2004) 1.67
Molecular mechanism of TNF signaling and beyond. Cell Res (2005) 1.66
Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. J Clin Gastroenterol (2014) 1.55
Immunopathology of inflammatory bowel disease. World J Gastroenterol (2014) 1.36
Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol (2015) 1.33
Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol (2015) 1.23
Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. Gastroenterology (2011) 1.20
Methodology, Not Concept of Fecal Microbiota Transplantation, Affects Clinical Findings. Gastroenterology (2015) 1.13
Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc (2014) 1.03
Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo. Eur J Immunol (2002) 1.02
Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology (2015) 1.01
Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res (2014) 0.97
The intestinal microbiota and host immune interactions in the critically ill. Trends Microbiol (2013) 0.95
Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med (2015) 0.94
The beneficial effect of Rheum tanguticum polysaccharide on protecting against diarrhea, colonic inflammation and ulceration in rats with TNBS-induced colitis: the role of macrophage mannose receptor in inflammation and immune response. Int Immunopharmacol (2008) 0.93
A patient with severe Crohn's colitis responds to Faecal Microbiota Transplantation. J Crohns Colitis (2013) 0.92
Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis (2015) 0.91
Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis (2013) 0.86
Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells. Gastroenterology (2005) 0.85
Disease monitoring in inflammatory bowel disease. World J Gastroenterol (2015) 0.80
Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World J Gastroenterol (2015) 0.78